| Bluestone Medical Center | |
|
324 Oakvale Rd Ste 12 Princeton WV 24740-3829 | |
| (681) 282-5576 | |
| (681) 282-5583 |
| Full Name | Bluestone Medical Center |
|---|---|
| Speciality | Clinic/Center |
| Location | 324 Oakvale Rd Ste 12, Princeton, West Virginia |
| Authorized Official Name and Position | Linda Hutchens (CEO) |
| Authorized Official Contact | 3044315499 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Bluestone Medical Center 3997 Beckley Rd Princeton WV 24740-7660 Ph: (304) 431-5499 | Bluestone Medical Center 324 Oakvale Rd Ste 12 Princeton WV 24740-3829 Ph: (681) 282-5576 |
| NPI Number | 1437508314 |
|---|---|
| Provider Enumeration Date | 06/10/2016 |
| Last Update Date | 02/24/2021 |
| Medicare PECOS PAC ID | 3577505221 |
|---|---|
| Medicare Enrollment ID | O20160815002864 |
News Archive
Children's growth disorders can be detected earlier and more efficiently with the help of new growth monitoring tools, according to research from the University of Eastern Finland. These tools include up-to-date growth reference curves, evidence-based screening cut-off values for abnormal growth and automated growth monitoring based on electronic health records.
The US Food and Drug Administration has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease (ECD).
Researchers from Boston Medical Center and Boston University School of Public Health have found that individuals who do not speak English at home are less likely to receive colorectal cancer screenings as compared to those who do speak English at home. The findings, which currently appear on-line in the Journal of General Internal Medicine, suggest that patient-provider language barriers play a role in health-care disparities, and that providers should promote the importance of CRC screening to non-English speaking patients.
Cellectis, the genome engineering specialist, has announced successfully programming cells from the immune system (T cells) to kill cancer cells. This technological breakthrough was revealed for the first time ever on Saturday, October 27th at the congress of the ESGCT (European Society of Gene & Cell Therapy) in Versailles, outside Paris.
Orexo AB (STO:ORX) today announced that it has obtained positive results in a clinical study with OX219, which is being developed for the treatment of opioid dependence.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437508314 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | 2WV7X5S256 (West Virginia) | Primary |
News Archive
Children's growth disorders can be detected earlier and more efficiently with the help of new growth monitoring tools, according to research from the University of Eastern Finland. These tools include up-to-date growth reference curves, evidence-based screening cut-off values for abnormal growth and automated growth monitoring based on electronic health records.
The US Food and Drug Administration has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease (ECD).
Researchers from Boston Medical Center and Boston University School of Public Health have found that individuals who do not speak English at home are less likely to receive colorectal cancer screenings as compared to those who do speak English at home. The findings, which currently appear on-line in the Journal of General Internal Medicine, suggest that patient-provider language barriers play a role in health-care disparities, and that providers should promote the importance of CRC screening to non-English speaking patients.
Cellectis, the genome engineering specialist, has announced successfully programming cells from the immune system (T cells) to kill cancer cells. This technological breakthrough was revealed for the first time ever on Saturday, October 27th at the congress of the ESGCT (European Society of Gene & Cell Therapy) in Versailles, outside Paris.
Orexo AB (STO:ORX) today announced that it has obtained positive results in a clinical study with OX219, which is being developed for the treatment of opioid dependence.
› Verified 7 days ago
Bluestone Primary Care Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 106 Thorn St, Princeton, WV 24740 Phone: 681-282-5609 Fax: 304-936-6157 | |
Total Life Family Practice Center Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 118 12th Street Ext, Princeton, WV 24740 Phone: 304-425-9568 Fax: 304-425-2744 | |
Faith Family Helalth Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 617 Mercer St, Princeton, WV 24740 Phone: 304-887-3530 | |
Princeton Family Medicine, Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 904 Harrison St, Princeton, WV 24740 Phone: 304-431-7100 Fax: 304-431-7112 | |
Midtowne Family Practice Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 403 12th Street Ext, Princeton, WV 24740 Phone: 304-431-9998 Fax: 304-425-0782 | |
Southern Highlands Community Mental Health Center, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 200 12th Street Ext, Princeton, WV 24740 Phone: 304-425-9541 Fax: 681-282-5558 | |
Blue Ridge Internal Medicine Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 407 12th Street Ext, Princeton, WV 24740 Phone: 304-487-0232 Fax: 304-487-0285 |